Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 2627 • ACR Convergence 2025
Risk of Adverse Pregnancy Outcomes in Individuals with Rheumatic Diseases Using Prenatal Antirheumatic Drugs: a Population-Based Cohort Study
Shenthuraan Tharmarajah¹, Dharini Mahendira², Swaleh Hussain¹, Howard Berger³, Sara Guilcher⁴, Lisa McCarthy⁴ and Mina Tadrous¹, ¹University of Toronto, Toronto, ON, Canada, ²St Michael's Hospital, Toronto, Canada, ³St. Michael's Hospital, Toronto, Canada, ⁴University of Toronto, Toronto, Canada
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are the primary class of drug therapies generally used to treat rheumatic diseases, such as rheumatoid arthritis (RA), systemic lupus…
Abstract Number: 1054 • ACR Convergence 2025
Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Ye Liu¹, Hongke Wu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Polypharmacy is a major concern in osteoporosis (OP) management, especially in older adults. Romosozumab (romo), approved in April 2019, is a parenteral OP medicine…
Abstract Number: 2571 • ACR Convergence 2025
Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
Griffin Reed¹, Jeffrey Yang¹, Georges El Hasbani¹, Cynthia Crowson², Hannah Langenfeld¹, Jeffrey Sparks³, Bryant England⁴, gabriela Schmajuk⁵, Kaleb Michaud⁴, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Methotrexate laboratory monitoring is highly resource intensive, and recent evidence questions whether the true toxicity of methotrexate has been over-estimated. Therefore, we aimed to…
Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 2519 • ACR Convergence 2025
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Shiamak Cooper¹, Asim Khanfar², Yousef al-mabrouk³, Omar Hamdan⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY, ³Prince Hanza Hospital, Amman, Jordan, ⁴University of Jordan, Az-Zarqa, Jordan, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Avacopan, a C5a receptor inhibitor, is used as an adjunctive treatment for ANCA-associated vasculitis. Previous studies have highlighted its efficacy in reducing glucocorticoid use…
Abstract Number: 1042 • ACR Convergence 2025
Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Eric Roberts¹, gabriela Schmajuk², Diana Ung³, Mackenzie Clark³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA
Background/Purpose: In 2023 patent exclusivity for adalimumab expired and nine biosimilars were introduced to the U.S. market with a tenth launched in May 2024. The…
Abstract Number: 2343 • ACR Convergence 2025
Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Anil Regmi³, Mayra Goreja⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Parkview Health, Fort Wayne, IN, ⁴Rochester General Hospital, Rochester, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as secukinumab and ixekizumab, are used for their anti-inflammatory effects in conditions like psoriasis and ankylosing spondylitis. IL-17 signaling has…
Abstract Number: 0666 • ACR Convergence 2025
Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
Sarah Crisci, New York University, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with heterogeneous symptoms, complicating diagnosis and treatment. Historically, treatment included broad immunosuppressants, but real-world data…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Sachalee Campbell¹, Laura Daniel², Puran Nepa², Otis Wilson³, Alyson L. Dickson³, Katherine Murray³, William D. Dupont³, Adriana Hung³, Wayne A. Ray³, Michael Stein⁴ and Cecilia P. Chung², ¹University of Miami, Miami, FL, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³Vanderbilt University Medical Center, Vanderbilt, TN, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…
Abstract Number: 2214 • ACR Convergence 2025
Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
Sadaf Sediqi¹, leo lu², J. Antonio Aviña-Zubieta³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) can pose an increased risk of adverse pregnancy outcomes such as preeclampsia and preterm delivery. Hydroxychloroquine (HCQ), commonly used to…
Abstract Number: 0479 • ACR Convergence 2025
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Shiamak Cooper³, Sanjana Thimmannagari¹ and Anthony Ocon⁴, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Irondequoit, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are immunomodulatory agents commonly used in the treatment of rheumatoid arthritis and COVID-19. Prior studies have implicated…
Abstract Number: 2087 • ACR Convergence 2025
Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis
Erfan Afshar¹ and Andrew Long², ¹VCUSOM, Richmond, VA, ²Virginia Commonwealth University Health System, Midlothian, VA
Background/Purpose: Carbamazepine has shown chondroprotective effects in OA animal models by modulating Nav1.7 channels. This study aimed to examine the association between Carbamazepine use and…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 2008 • ACR Convergence 2025
Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
Natalie McCormick¹, Sharan Rai², Chio Yokose³, leo lu⁴, Robert Terkeltaub⁵, Lama Nazzal⁶, Huilin Li⁶, Dylan Dodd⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Retired, San Diego, CA, ⁶NYU Langone, New York, NY, ⁷Stanford University, Palo Alto, CA, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: As reported in Cell Press journals,1,2 intestinal commensal purine-degrading bacteria anaerobically degrade urate to anti-inflammatory short chain fatty acids, including butyrate, and thus may…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].